## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Angeline Ingrid Bartholomeusz, et al.

Examiner:

Unassigned

Serial No.:

10/576,906

**Art Unit:** 

Unassigned

Filed:

April 21, 2006

Docket:

19781

For:

**HBV VARIANTS DETECTION** 

Dated:

October 19, 2006

AND APPLICATION

Mail Stop PCT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

- 1. PCT International Publication No. WO 03/087351 A1, published October 23, 2003;
- 2. PCT International Publication No. WO 03/066841, published August 14, 2003;
- 3. PCT International Publication No. WO 2004/031224 A2, published April 15, 2004;
- 4. PCT International Publication No. WO 00/61758, published October 19, 2000;

## CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 19, 2006

Xiaochun Zhu

5. Torresi J. et al., "Restoration of Replication Phenotype of Lamivudine-Resistant Hepatitis B Virus Mutants by Compensatory Changes in the "Fingers" Subdomain of the Viral Polymerase Selected as a Consequence of Mutations in the Overlapping S Gene", *Virology*, 299:88-99 (2002); and

6. Ono S.K. et al., "The Polymerase L528M Mutation Cooperates with Nucleotide Binding-Site Mutations, Increasing Hepatitis B Virus Replication and Drug Resistance", *The Journal of Clinical Investigation*, 107(4):449-455 (2001).

The references were cited in an International Search Report dated December 20, 2004 received from the Australian Patent Office. Applicants are submitting copies of the above-cited references. A copy of the International Search Report was previously submitted by Applicants on April 21, 2006. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R.§ 1.97(b), no statement or fee is required.

Respectfully submitted,

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343

XZ:dg

				Docket Number (Optional) 19781		Application Number 10/576,906				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Angeline Ingrid Bartholomeusz, et al.					
				/	3 2006	Filing Date April 21, 200		Group Art Unit	ssigned	
•				/B	S PATION		U	Olla	ssigned	
*EXAMINER		Τ_		DATE U.	T. A. C.	DOCUMENTS	1		FILING	DATE
· INITIAL	REF	<u> </u>	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		OPRIATE
						-				
									i de	
		_		U.S. PATEN	T APPLICA	TION PUBLICATIONS				
*EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	DATE
					<u> </u>					
				FORE	EIGN PATEN	NT DOCUMENTS				
	REF		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	Trans YES	slation NO
		W	O 03/087351 A1	10/23/03	PCT				J	
		WO 03/066841  WO 2004/031224 A2  WO 00/61758		8/14/03	РСТ				7	
				4/15/04	PCT				>	
				10/19/00	РСТ				J	
				OTHER	DOCUMENT	TS (Including Author	, Title, Date, I	Pertinent Pages, Et	(c.)	
			Torresi J. et al., "Resto Compensatory Changes Overlapping S Gene",	ration of Replica s in the "Fingers' Virology, 299:88-	tion Phenot ' Subdomai 99 (2002)	type of Lamivudine-Resist n of the Viral Polymerase	ant Hepatiti Selected as	s B Virus Mutar a Consequence o	its by of Mutation	is in the
			Ono S.K. et al., "The P B Virus Replication and	olymerase L528N d Drug Resistanc	1 Mutation e", The Jou	Cooperates with Nucleoti rnal of Clinical Investigat	de Binding-Stion, 107(4):4	Site Mutations, I 149-455 (2001)	Increasing	Hepatitis
EXAMINER				DATE CONSIDERED						
			itation considered, whether copy of this form with next			ce with MPEP Section 609; I	Oraw line thro	ugh citation if not	in conform	ance and
						/DEV/OF D				

-						164		
TRAI	NSMITTA	L OF INFORMA (Under 37 CFF	Docket No. 上, 19781					
In Re Ap	oplication Of	f: Angeline Ingrid	Bartholomeusz, et al.  OCT 2 3 2006					
Applic	ation No.	Filing Date		Customer No.	Group Art Unit	Init Confirmation No.		
10/576,906		April 21, 2006	Unassigned	23389	Unassigned	Unassigned		
Title: HBV VARIANTS DETECTION AND APPLICATION								
	-		Address to: Commissioner for Patent: P.O. Box 1450 Alexandria, VA 22313-145					
1. 🗵	37 CFR 1.97(b)  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.							
			37 CFR 1.97(c)					
2.	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:							
	☐ the s	statement specified in	n 37 CFR 1.97(e);					
		•	OR					
	☐ the f	fee set forth in 37 CF	R 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 19781			
In Re Application of: Angeline Ingrid Bartholomeusz, et al.								
Application No. Filing Date Examiner Customer No.					Group Art Unit	oup Art Unit   Confirmation No		
10/576,906	April 21, 2006	Unassigned		23389	Unassigned	Unassigned		
Title: HBV VARI	ANTS DETECTION	AND APPLICATION	Ň					
The Director as described as de	The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP  as described below.  Charge the amount of Credit any overpayment. Credit any overpayment. Charge any additional fee required.  Payment by credit card. Form PTO-2038 is attached.  WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.  Certificate of Transmission by Facsimile*  Certificate of Mailing by First Class Mail  I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on							
Xiaochun Zhu Registration No. 56, Scully, Scott, Murpi 400 Garden City Pla Garden City, New Y 516-742-4343	hy & Presser, P.C. aza, Suite 300		Dated: •	October 19, 200	06			
CC:								